Lantheus (LNTH) AI Stock Analysis

• Market Cap: $5.02B
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): 13.8
• Beta (1Y): 0.63
• Revenue Growth: 5.75%
• EPS Growth: -37.03%
• Country: US
• Employees: 808
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.57
• Shares Outstanding: 69,185,840
• 10 Day Avg. Volume: 820,962
• 30 Day Avg. Volume: 1,003,970
• PEG Ratio: -3.52
• Price to Book (P/B): 5.69
• Price to Sales (P/S): 4.04
• P/FCF Ratio: 12.55
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: 3.73
• Enterprise Value/Gross Profit: 5.85
• Enterprise Value/Ebitda: 13.43
• 1Y Price Target: $87.83
• Price Target Upside: 60.10% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 66 Neutral
• Price Target: $56.00 ▲(2.08% Upside)

Lantheus's overall stock score reflects a solid financial foundation and positive corporate developments. However, bearish technical indicators and challenges in maintaining market share weigh on the score. Strategic initiatives and a reasonable valuation provide some support, but the stock faces near-term pressures.

Positive Factors

Growth Potential

Lantheus continues to be well positioned for longer-term growth given their existing market leadership in the PSMA PET imaging space with Pylarify, and expansion into neurodiagnostics & other areas of oncology via recent acquisitions.

Stock Repurchase

The Board of Directors authorized the repurchase of up to $400M of LNTH's common stock, which can be seen as a vote of confidence in the company's future value.

Strategic Acquisitions

The acquisition of Life Molecular Imaging added the FDA-approved NEURACEQ to LNTH's portfolio, expanding its diagnostic and therapeutic capabilities.

Negative Factors

Competitive Pressure

Sustained competitive pressure is creating headwinds for the company's lead asset, PYLARIFY, which resulted in a notable stock price drop.

Market Share Loss

Revenue came in below expectations at $378 million, versus Street consensus of $388 million and our estimate of $383 million, attributable to increased competition, likely from Posluma, that resulted in a loss of market share.

Revenue Guidance Reduction

The company reduced FY25 revenue guidance to $1.475B - $1.51B from the previous range of $1.55B - $1.585B, indicating challenges in maintaining expected growth.

Lantheus Business Overview & Revenue Model

Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

How the Company Makes Money

Lantheus makes money by selling its diagnostic imaging agents and products to hospitals, clinics, and other healthcare providers. The company's revenue is primarily generated through the commercialization of its proprietary imaging agents, which are used to enhance the diagnostic capabilities of PET and SPECT imaging technologies. Lantheus also engages in strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to expand its product offerings and reach in the market. Additionally, the company's revenue streams are supported by ongoing research and development efforts that lead to the introduction of new products and enhancements to existing ones, thereby sustaining and growing its market presence.

Lantheus Financial Statement Overview

Summary

Lantheus showcases a strong financial position across all verticals. The income statement reflects impressive growth and profitability, while the balance sheet indicates financial stability and efficient leverage management. The cash flow statement highlights robust cash generation and liquidity. The company's financial performance is characterized by healthy growth, strong margins, and efficient cash management.

Income Statement

Lantheus exhibits impressive growth and profitability metrics. The TTM (Trailing-Twelve-Months) shows a robust gross profit margin of 64.05% and a strong net profit margin of 16.55%. Revenue growth has been exceptional, with significant increases year-over-year. The EBIT and EBITDA margins also reflect strong operational efficiency. Overall, the company demonstrates excellent revenue growth and healthy profitability in its income statement.

Balance Sheet

Lantheus maintains a solid balance sheet with a debt-to-equity ratio of 0.53, indicating moderate leverage. The company has a strong equity position, with an equity ratio of 56.65%, which signifies financial stability. Return on equity (ROE) is also impressive at 21.84%, highlighting effective use of equity to generate profits. The balance sheet reflects a healthy financial structure with a balanced approach to debt and equity.

Cash Flow

Lantheus demonstrates strong cash flow performance. The operating cash flow to net income ratio is 2.06, indicating efficient cash generation relative to net income. Free cash flow remains robust with a modest growth rate. The free cash flow to net income ratio of 1.86 suggests effective conversion of profits into cash. Overall, the company exhibits strong cash flow management and adequate liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.52B	1.53B	1.30B	935.06M	425.21M	339.41M
Gross Profit	969.38M	988.29M	709.54M	581.70M	187.69M	138.76M
EBITDA	422.57M	515.27M	491.00M	81.83M	-25.00M	22.69M
Net Income	271.00M	312.44M	326.66M	28.07M	-71.28M	-13.47M
Balance Sheet
Total Assets	2.12B	1.98B	1.65B	1.32B	863.78M	869.82M
Cash, Cash Equivalents and Short-Term Investments	695.57M	912.81M	713.66M	415.65M	98.51M	79.61M
Total Debt	796.00K	619.44M	616.95M	558.07M	174.76M	218.40M
Total Liabilities	949.29M	892.33M	835.26M	874.11M	399.35M	355.62M
Stockholders Equity	1.17B	1.09B	815.89M	447.15M	464.44M	514.21M
Cash Flow
Free Cash Flow	478.61M	493.13M	258.70M	263.43M	41.78M	3.92M
Operating Cash Flow	527.46M	544.75M	305.26M	281.78M	53.92M	16.40M
Investing Cash Flow	-370.59M	-226.01M	5.94M	-276.55M	3.68M	-4.91M
Financing Cash Flow	-218.42M	-118.54M	-13.06M	311.69M	-39.33M	-21.86M

Lantheus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 54.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Negative. The current price of 54.86 is below the 20-day moving average (MA) of 71.70, below the 50-day MA of 76.53, and below the 200-day MA of 89.36, indicating a bearish trend. The MACD of -4.63 indicates Positive momentum. The RSI at 25.45 is Positive, neither overbought nor oversold. The STOCH value of 40.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LNTH.

Lantheus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NBIX	72 Outperform	$12.73B	37.91	13.39%	―	18.42%	1.47%
RDY	67 Neutral	$11.54B	17.09	18.36%	0.67%	13.03%	-0.49%
LNTH	66 Neutral	$5.02B	13.78	24.71%	―	5.75%	-37.03%
VTRS	57 Neutral	$10.54B	―	-19.77%	5.49%	-6.88%	-6809.78%
TEVA	55 Neutral	$18.31B	―	-2.31%	―	2.43%	64.37%
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.37%	15.48%	-2.68%
PRGO	51 Neutral	$3.25B	―	-1.32%	4.79%	-2.32%	35.46%

Lantheus Corporate Events

Lantheus Announces FDA Acceptance of New Drug Application

On August 6, 2025, Lantheus announced the FDA’s acceptance of a new drug application for a new formulation of its piflufolastat F-18 imaging agent, which could significantly increase patient access. The company also reported its second-quarter financial results, highlighting a revenue of $378 million and a strategic acquisition of Life Molecular Imaging, which expands its product portfolio and market reach. Additionally, Lantheus’ board authorized a $400 million stock repurchase program, reflecting confidence in its long-term growth strategy.

The most recent analyst rating on (LNTH) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Lantheus stock, see the LNTH Stock Forecast page.

Lantheus Completes Acquisition of Life Molecular Imaging

On July 21, 2025, Lantheus completed its acquisition of Life Molecular Imaging Limited, enhancing its capabilities in Alzheimer’s disease diagnostics with the addition of Neuraceq, an F-18 PET imaging agent. The acquisition, valued at $350 million, strengthens Lantheus’s international presence and R&D capabilities. Additionally, Dr. Ludger Dinkelborg, former CEO of Life Molecular Imaging, was appointed as Lantheus’s Head of Research and Development, effective August 1, 2025, to lead various strategic areas, including Clinical Development and AI/Biomarkers Solutions.

The most recent analyst rating on (LNTH) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Lantheus stock, see the LNTH Stock Forecast page.